Cancer

Poolbeg Pharma PLC Announces Director/PDMR Shareholding

Director Share PurchaseLONDON, UK / ACCESSWIRE / February 22, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), 'Poolbeg' or the 'Company'), a biopharmaceutical…

11 months ago

Cantargia Publishes Year-End Report for 2023

LUND, SWEDEN / ACCESSWIRE / February 22, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB (publ); Nasdaq Stockholm: CANTA) today announced…

11 months ago

New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera

- Trial met the primary efficacy endpoint achieving a clinically and statistically significant response in maintaining hematocrit control below 45%…

11 months ago

Taglich Brothers Publishes First Coverage Report on Cosmos Health with a Price Target of $4, a Nearly Five-Fold Increase from Current Share Price

CHICAGO, IL / ACCESSWIRE / February 21, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,…

11 months ago

bioAffinity Technologies News Update

SAN ANTONIO--(BUSINESS WIRE)--#ATS--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the…

11 months ago

Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

UDENYCA ONBODY™ UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqvFull Prescribing Information, including instructions for use, is…

11 months ago

Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

HANOVER, MD, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical…

11 months ago

Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy

Partnership Brings Pioneering Approach to Incorporating Advanced Colorectal Cancer Detection Into Country’s Healthcare SystemBERKELEY, Calif. and MAINZ, Germany, Feb. 21,…

11 months ago

Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024

CAMBRIDGE, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering…

11 months ago